BioLineRx Ltd. - 예탁증서(보통주)

SecurityBLRX / BioLineRx Ltd. - Depositary Receipt (Common Stock)
InstitutionUBS Group AG
Latest Disclosed Ownership529 shares
Latest Disclosed Value $ 1,217
UBS Group AG reports 72.89% decrease in ownership of BLRX / BioLineRx Ltd. - Depositary Receipt (Common Stock)

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 529 shares of BioLineRx Ltd. - Depositary Receipt (Common Stock) (US:BLRX) valued at $1,222 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 1,951 shares of BioLineRx Ltd. - Depositary Receipt (Common Stock). This represents a change in shares of -72.89% during the quarter. The current value of the position is $1,777 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F BIOLINE RX SPONSORED ADR 09071M304 529 -1,422 -72.89 1 -80.00 0.0000
2026-01-29 2025-12-31 13F BIOLINE RX SPONSORED ADR 09071M304 1,951 -4,436 -69.45 5 -79.17 0.0000
2025-11-13 2025-09-30 13F BIOLINE RX SPONSORED ADR 09071M304 6,387 6,387 24 0.0000
2025-08-14 2025-06-30 13F BIOLINE RX SPONSORED ADR 09071M304 0 -71 -100.00 0 0.0000
2025-05-13 2025-03-31 13F BIOLINE RX SPONSORED ADR 09071M304 71 71 0 0.0000
2023-05-12 2023-03-31 13F AKANDA COMMON SHARES 00971M106 0 -62,810 -100.00 0 -100.00
2023-02-08 2022-12-31 13F AKANDA COMMON SHARES 00971M106 62,810 53,204 553.86 9 125.00 0.0000
2022-11-10 2022-09-30 13F AKANDA COMMON SHARES 00971M106 9,606 5,441 130.64 4 33.33 0.0000
2022-08-10 2022-06-30 13F AKANDA COMMON SHARES 00971M106 4,165 1,853 80.15 3 -83.33 0.0000
2022-05-16 2022-03-31 13F AKANDA COMMON SHARES 00971M106 2,312 2,312 18 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.